Neil Stahl, EVP Research and Development at REGENERON PHARMACEUTICALS, INC. (REGN), sold 70,456 shares at $518.63 ($36.3M) on 2021-05-17, disclosed to the SEC on 2021-05-18.
Seasonal sale ($36.3M) by EVP Research and Development — this insider has traded REGN in May in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 435 | $0 | 0.0% |
| 2 | $516.69 | 7,204 | $3.7M | 10.3% |
| 3 | $516.69 | 27,775 | $14.4M | 39.6% |
| 4 | $518.63 | 3,379 | $1.8M | 4.8% |
| 5 | $518.63 | 3,379 | $1.8M | 4.8% |
| 6 | $519.47 | 10,336 |
| $5.4M |
| 14.8% |
| 7 | $519.47 | 10,336 | $5.4M | 14.8% |
| 8 | $520.17 | 3,806 | $2.0M | 5.5% |
| 9 | $520.17 | 3,806 | $2.0M | 5.5% |
| Total | $514.88 avg | 70,456 | $36.3M | 100% |
| Filing → |
| REGN | SELL | 2023-08-23 | $19.6M | — | Filing → |
| REGN | SELL | 2022-08-08 | $28.4M | — | Filing → |
| REGN | SELL | 2020-05-11 | $5.9M | — | Filing → |